Interviews with Pharma and Biotech Global Leaders
Refine Search
Biotechnology
Nine months out from landing an additional $35 million in seed funding, Relation has more news – a big pharma collaboration. The group has announced a $45 million upfront deal, including a $15 million equity investment with UK pharma group GSK. 13 December 2024
Biotechnology
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma. 28 November 2024
Pharmaceutical
Germany's Merck has spent more than 25 years researching and developing solutions for advancing multiple sclerosis (MS) care. 21 November 2024
Biotechnology
German biotech CatalYm has followed up a groundbreaking 2023 with an impressive 2024. 19 November 2024
Biotechnology
This week, we discuss a novel AI-driven approach to drug development, and its potential to transform the treatment of cancer and autoimmune diseases. 14 November 2024
Biotechnology
Where once the state of play in the cell and gene therapy space was mostly limited to hope and hype around what might be to come, this is increasingly being replaced by action, on-market therapies and genuine expectation of reaching patients—provided companies can avoid some of the sector’s notorious pitfalls. 16 October 2024
Biotechnology
At last month’s European Academy of Dermatology and Venereology (EADV) congress in Amsterdam, Novartis presented new early and long-term Phase III data for remibrutinib in chronic spontaneous urticaria (CSU). 14 October 2024
Pharmaceutical
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
Pharmaceutical
Amid an explosion in investment and development milestones seen over the past decade, the age of radiopharmaceuticals as both diagnostics and as therapeutics is very much arriving. 5 September 2024
Pharmaceutical
Accord Healthcare might not be as well-known as certain preeminent pharma corporations in the UK and Europe, but you would struggle to find any company making a greater contribution to the production and supply of medicines across the continent. 14 August 2024
Pharmaceutical
Plenty of companies in the pharmaceutical industry talk the talk when it comes to focusing on patients. 6 August 2024
Biotechnology
It is not every day that an Italian biotech company raises 23 million euros ($24.7 million) in a Series A financing. 17 June 2024
Pharmaceutical
Privately-held company GAIA has had more than a front-row seat to observe the arrival of digital therapeutics and applications of AI in pharma over the past quarter century. 4 June 2024
Interview
With a steady flow of oncology results emerging from the ongoing ASCO meeting, a company such as Pierre Fabre, which does not have major data to present, might not usually claim the spotlight. 3 June 2024
Biotechnology
Marc de Garidel, chief executive of French clinical-stage biotech Abivax (Nasdaq: ABVX), has good reason for his belief in the company’s pioneering lead asset, obefazimod. 13 May 2024
Pharmaceutical
A Q&A with the man who heads the UK business of the privately-held Italian drugmaker. 3 May 2024
Pharmaceutical
Privately-held Isotope Technologies Munich (ITM) is not just the radiopharmaceutical company that can do it all - from manufacturing and supplying medical radioisotopes to developing a broad precision oncology pipeline, including two Phase III studies. 26 April 2024
Biotechnology
German firm Tubulis has just announced a 128 million euros ($138.8 million) Series B2 financing. 15 March 2024
Pharmaceutical
Staying true to her values is not a secondary consideration for Dr Dennise Broderick in her career and leadership of Galen, but rather is front and central to every action she takes. 7 March 2024
Biotechnology
Since the approval of the first CAR-T in 2017, T cell therapies have revolutionized the treatment of some blood cancers, and are one of the few cancer treatments to drive cures. 12 February 2024
Biotechnology
At the national level, drug pricing continues to be a hot button issue for lawmakers, drugmakers and patients in the USA. At the state level, could Prescription Drug Affordability Boards (PDAB) be the answer? 4 March 2022
Pharmaceutical
Bold investments in BlueRock, AskBio and Vividion have shown the ambition of Bayer’s new approach towards R&D, and another sign of intent was the German company’s appointment of Christian Rommel in late 2020. 28 February 2022
Biotechnology
Ever increasing investments are being made in artificial intelligence, as drugmakers spy an opportunity to drive efficiencies and spur innovation. In this episode, we discuss an exciting new collaboration between pharmaceutical majors in the field of AI. 30 December 2021
Biotechnology
The Johnson & Johnson unit Janssen has been active in neuroscience since the beginnings of the company, with its first product coming in this space, so each new major breakthrough in the area is a continuation of a rich tradition. 1 December 2021
Pharmaceutical
Not many companies in the pharmaceutical sector can say that they have kept growing and targeting growth through the pandemic, while maintaining the same commitment to their values, patients and employees. 26 November 2021
Pharmaceutical
In October 2016, Gabriel Baertschi left his role as president and general manager of AstraZeneca in Japan to take the top job at Germany’s Grünenthal Group. 27 October 2021
Pharmaceutical
New data from a survey of patients prescribed medical cannabis to treat pain shows that 86% found it to be more effective than other medication that they had previously taken. 29 July 2021
Pharmaceutical
There are pharma companies that have some degree of focus on women’s health conditions, but none to date have had such an ambitious mission in the field as newly-launched Organon. 2 July 2021
Pharmaceutical
Japanese drugmaker Takeda’s $62 billion acquisition of rare disease specialist Shire showed its ambition to be a leader in the space. 21 June 2021
Pharmaceutical
Getting celiac disease (CD) diagnosed can be a long and difficult path for patients, and with no effective treatments available, the outcome is often a burdensome impact on quality of life. 15 June 2021
Biotechnology
At this year’s ASCO meeting, Bristol Myers Squibb will present the first data from a Phase III trial evaluating a LAG-3-blocking antibody. 20 May 2021
Biotechnology
Interest in the therapeutic potential of psychedelics is at an all-time high. 11 May 2021
Biotechnology
Danish company Genmab has a lot going on this year, as chief executive Jan van de Winkel tells The Pharma Letter. 16 April 2021
Biotechnology
For biotech companies, the prospect of receiving non-dilutive, non-recourse funding to advance their assets even through the early stages of clinical development may sound too good to be true. 16 April 2021
Biotechnology
Californian aging specialist CohBar is using mitochondrial science to treat diseases, but chief executive Steven Engle doesn’t rule out offering a “cure for ageing” at some point. 23 March 2021
Biotechnology
Where the application of ribonucleic acid (RNA) in medicine is concerned, two companies have so far led the way. 17 February 2021
Pharmaceutical
Large, privately-held European drugmakers are not typically identified with dynamism and a bold, acquisitive business strategy. 22 January 2021
Pharmaceutical
No company has been exclusively focused on neuroscience for as long as Lundbeck (CPH: LUN). 5 January 2021
Pharmaceutical
Nobody can doubt that the pharmaceutical industry is home to some very smart and ambitious minds, but it is also true that sometimes the sector has missed out to other careers in attracting top talent. 4 December 2020
Biotechnology
German drugmaker Bayer has generally preferred in-licensing deals and other collaborations to multi-billion dollar acquisitions, so executives must have been highly impressed by what they saw of Asklepios BioPharmaceutical (AskBio) to spend $2 billion upfront on buying the US biotech, along with up to $2 billion more depending on certain milestones. 23 November 2020
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze